These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 11439941)
21. Making right turns in the HIV pharmacology maze. 5th International Workshop on Clinical Pharmacology of HIV Therapy. April 1-3, 2004, Rome. Mascolini M IAPAC Mon; 2004 Jul; 10(7):232-57. PubMed ID: 15624246 [No Abstract] [Full Text] [Related]
22. [Primary resistance to antiretroviral agents]. Soriano V; María Miró J; Guerrero A Enferm Infecc Microbiol Clin; 2001 Feb; 19(Monografico):22-5. PubMed ID: 11428054 [No Abstract] [Full Text] [Related]
23. Basic principles and clinical implications. Abstracts from the XIV International HIV Drug Resistance Workshop. June 7-11, 2005. Québec City, Québec, Canada. Antivir Ther; 2005; 10(4):S3-181. PubMed ID: 16163812 [No Abstract] [Full Text] [Related]
24. [Resistance to nucleoside reverse transcriptase inhibitors]. Leal M; Santamaría JM Enferm Infecc Microbiol Clin; 2001 Feb; 19(Monografico):26-9. PubMed ID: 11428055 [No Abstract] [Full Text] [Related]
25. ICAAC study on resistance. Burgess G Surviv News (Atlanta Ga); 2002 Feb; ():14. PubMed ID: 11870996 [No Abstract] [Full Text] [Related]
26. ICAAC. New resistance findings presented at annual conference. Rodriguez E Posit Living; 2002; 11(1):16. PubMed ID: 11942289 [No Abstract] [Full Text] [Related]
32. Abstracts of the XIV International HIV Drug Resistance Workshop: Basic Principles and Clinical Implications. 7-11 June 2005, Quebec City, Canada. Antivir Ther; 2005; 10 Suppl 1():P3-4, S3-181. PubMed ID: 16334453 [No Abstract] [Full Text] [Related]
33. [HIV infection. Virus resistance: development and prevention]. Link R; Miller V; Fätkenheuer G; Manegold C; Harrer T Med Monatsschr Pharm; 1999 Mar; 22(3):86-8. PubMed ID: 10223868 [No Abstract] [Full Text] [Related]
34. HIV genotype and phenotype--arresting resistance? Flexner C JAMA; 2000 May; 283(18):2442-4. PubMed ID: 10815093 [No Abstract] [Full Text] [Related]
35. Companies aim at new HIV targets. Brower V Nat Biotechnol; 1996 Sep; 14(9):1079. PubMed ID: 9669875 [No Abstract] [Full Text] [Related]
36. How testing for HIV resistance influences therapeutic decision making. Analysis of a sample of 600 clinicians. Mascolini M; Wensing AM; Boucher CA IAPAC Mon; 2001 Mar; 7(3):85-90. PubMed ID: 11697306 [No Abstract] [Full Text] [Related]
38. [Biological basis for generating resistance to antiretroviral drugs]. Alcamí J; Delgado R; Menéndez-Arias L Enferm Infecc Microbiol Clin; 2001 Feb; 19(Monografico):3-13. PubMed ID: 11428056 [No Abstract] [Full Text] [Related]
39. Intention-to-treat analysis of anti-HIV therapies and incidence of drug resistance after a year of treatment. Aizawa S; Ida S; Sakai-Hachiya A; Tanaka M; Takahashi Y; Hirabayashi Y; Sugiura W; Kimura S; Oka S Jpn J Infect Dis; 1999 Jun; 52(3):129-31. PubMed ID: 10507996 [No Abstract] [Full Text] [Related]
40. Reversibility of HIV drug resistance. Davenport MP Science; 2000 May; 288(5470):1299. PubMed ID: 10847833 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]